State Street’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

State Street’s Portfolio BTTX Stock Details BTTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-58,600	Closed	-$11.4K	–	4432
2023 Q4	$11.4K	Hold	58,600	–	–	﹤0.01%	4388
2023 Q3	$22.6K	Buy	58,600 +13,400	+30%	+$9.04K	﹤0.01%	4430
2023 Q2	$48.8K	Hold	45,200	–	–	﹤0.01%	4425
2023 Q1	$32.9K	Hold	45,200	–	–	﹤0.01%	4608
2022 Q4	$50.6K	Hold	45,200	–	–	﹤0.01%	4556
2022 Q3	$80K	Hold	45,200	–	–	﹤0.01%	4539
2022 Q2	$71K	Buy	+45,200	New	+$75.6K	﹤0.01%	4646
2022 Q1	–	Sell	-13,327	Closed	-$62K	–	4935
2021 Q4	$62K	Buy	+13,327	New	+$109K	﹤0.01%	4666

Other funds holding BTTX

CIAS

Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

State Street's BTTX Position: Q1 2024 in Review

State Street sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2024, closing a stake of 58,600 shares — an estimated $11.4K sold.

State Street first reported a position in BTTX in Q4 2021 and held it in 8 quarters. The position peaked at $80K in Q3 2022. 3 funds tracked by Wall St. Rank hold BTTX as of Q1 2024.

State Street reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
State Street sold 58,600 Better Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $11.4K.
State Street first reported a position in Better Therapeutics, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
State Street's Better Therapeutics, Inc. Common Stock position peaked at $80K in Q3 2022.
3 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2024.

Based on State Street's 13F filing for Q1 2024, filed 15 May 2024.